Australia's BCAL Diagnostics rises on deal to develop tests for breast cancer

BCAL Diagnostics

28/06/2022 06:36

** Shares of BCAL Diagnostics  BDX.AX  advance as much as
20% to A$0.072 - set for their biggest intraday pct rise since
March 22, if gains hold
    ** BCAL enters agreement with U.S. clinical research firm
Precion Inc to advance its blood-based test to detect breast
cancer  urn:newsml:reuters.com:*:nASXN8xsc
    ** Both parties to collaborate in developing standardised
biomarker tests, validate algorithm required for reporting
results and carry out clinical studies in the United States -
BDX
    ** Shares hit their highest level since June 17
    ** More than 349,000 shares change hands, compared with the
30-day average volume of about 139,000 shares
    ** Stock had fallen 52% this year, as of last close

 (Reporting by Anan Ashraf in Bengaluru)
 ((Anan.Ashraf@thomsonreuters.com;))